Brenipatide for Depression

(RENEW-MDD-1 Trial)

This trial tests a new treatment called brenipatide, an experimental drug, to determine if it can safely and effectively delay the return of major depressive symptoms when combined with standard depression care. Participants will receive either brenipatide or a placebo, a harmless pill with no active drug, alongside their usual treatment. The study aims to determine if brenipatide can help individuals maintain their mental health longer. Suitable candidates have major depressive disorder, are stable on their current medication, and can commit to study visits and tasks such as self-injecting medication and keeping a diary. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to a potentially groundbreaking treatment for depression.

The trial requires that you stay on your current stable medication for major depressive disorder.

Research has shown that brenipatide has undergone testing in various clinical settings to assess its safety and effectiveness. In earlier studies, most patients tolerated brenipatide well, experiencing mild to moderate side effects like headaches, nausea, and tiredness. Importantly, serious side effects directly linked to the drug have not been commonly reported.

Unlike other treatments for depression that typically involve oral medications like SSRIs or SNRIs, Brenipatide is administered subcutaneously, which might offer a new delivery method for patients. This drug has researchers excited because it potentially introduces a novel mechanism of action that targets depression differently from traditional options, possibly providing relief for those who haven't responded well to existing treatments. Additionally, the flexibility in dosing—offering multiple dose levels—might help tailor the treatment to individual patient needs, potentially improving outcomes and minimizing side effects.

Research has shown that brenipatide is being tested in this trial to determine its potential in reducing depression symptoms. Participants will receive one of three doses of brenipatide or a placebo, alongside standard treatments for depression. Studies suggest that brenipatide might help prevent the recurrence of major depression symptoms, potentially improving well-being for longer periods. Early results in similar conditions, such as bipolar disorder, have been promising, indicating that brenipatide can be used safely with current treatments. However, further research is needed to confirm its effectiveness.¹²³⁶⁷